Skip to main content

CLV: A New form of Vasculitis

Dr. Benjamin Turturice and Dr. Michael Putman | Abstract 2889 | ACR 2026 Orlando

Transcription

Hi, it's Mike Putman with RheumNow coming from ACR Convergence 2026. And I'm really excited to be interviewing Benjamin Terrier. Who discovered a new disease. So these are a new category of diseases. These are the same folks that brought us VEXAS, and we're here today to talk about clonal lymphoid vasculitis. So tell me what this is and how you found it.

So this is a new category of disease that we found by looking at clonal T-cells in patients that have a very distinct phenotype of vasculitis that's characterized by aneurysms in medium-sized vessels and patients with hypereosinophilic syndrome. And so we did whole genome sequencing on cells that were isolated from these patients and identified translocations causing these cells to traffic to vessels.

Very interesting. So for those who aren't familiar with Benjamin, he works in Peter Grayson's group and these are the same folks that brought us VEXAS. So after y'all showed us about VEXAS, all of a sudden I started finding all these people who are VEXAS adjacent. We had diagnosed some VEXAS. So what are the kind of things that you saw clinically that would cue people into these diseases?

Yeah, so one of the things is sort of the refractory nature of these conditions and the fact that things like our anti-cytokine therapies are temporizing or not as effective as we would expect them to be. And one of the things that we've learned about treating these conditions is that targeting the clone seems to be a little bit more effective.

Okay, tell me more about that. One problem I had with VEXAS is that we found them and then I wasn't sure what to do. We tried to JAK and it was kind of hard. So what can we do for this one?

So we've had several patients that have had refractory disease and we have used a medication called Romidepsin, which is something that rheumatologists are probably not familiar with. But it is a medication that was approved for peripheral T-cell lymphomas and it is very effective at depleting the clone in these patients.

So this is kind of cool. You actually have a thing to do for these people once you find them. Okay. Correct. And then give me a little more about the methods that you used to find them. You identified people who had kind of a funny clinical phenotype and what was that?

So these patients, they would meet definition for lymphoid variant hypereosinophilic syndrome based on the fact that they have hypereosinophilia, some affected tissues, and this sort of bizarre T-cell on flow cytometry, which is something that you could order as a clinical test. And all these patients had very distinct aneurysms in medium-sized vessels. So areas like the temporal artery or the coronary arteries or in their extremities. And you know, these patients were a little bit younger than what you would typically expect for GCA. So they were in their 20s, 30s, 40s when they were presenting with symptoms. So a little bit outside of what we typically expect for our older patients.

So younger population with a funky T-cell population, and then they present with aneurysms and hypereosinophilia. Do they always have hypereosinophilia? All of our patients had that — that'll be like a nice discriminatory piece of information where you say should I be worried about this or not? And you actually have a treatment for it. It's very exciting.

So what are the implications of this for these kinds of diseases at large? I think one of the lessons that I took from the VEXAS adventure was that there's probably a lot of diseases that are kind of hiding out within our patient population. So do you think there's more of these, or are there lessons to be learned?

Yeah, I think there's definitely more of these out there and there's probably more mutations than the ones that we described. I think one of the things that we were a little bit surprised by from this condition is that the clone size was actually really small. So this is something that might be missed on next generation sequencing of whole blood. And so I think part of the future of discovery in this is going to be how to find more of these in small clone populations.

Sounds challenging. So do these folks have to go to the NIH to see you guys, or what's the — who has the capacity? As of right now the sort of the genetic part of the testing is still research based. But these patients — the clone can at least be identified through things like clinical flow cytometry and through T-cell receptor PCR, which both of these things are available and can be ordered.

Okay. So there's an avenue to find it if you find these folks. So we're looking for people who have hypereosinophilia and multiple aneurysms and sort of a medium vessel vasculitis picture. This is very cool. What else would you like people to take home from this whole thing?

Again, I'd like to say that I think when you have these refractory patients, think of clonal disorders, and I think finding these mutations kind of helps reframe diseases and potentially offers new treatment options for patients.

I love it. That's very exciting. I think that a lot of the progress is going to be kind of chipping away and finding these things that you know currently we phenotype and now we're actually moving to more useful genetic or immunophenotypes that can actually get us there. Very cool. All right. Well, thanks so much. Good luck on your presentation later today. I'm sure it'll be great. And hoping this comes to a great journal sometime soon. Great. Thank you. Have a good one.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×